RELENZA
Country: Iżrael
Lingwa: Ingliż
Sors: Ministry of Health
Rapport ta 'Valutazzjoni Pubblika
(PAR)
21-03-2017
Xi dokumenti għal dan il-prodott mhumiex disponibbli bħalissa, tista 'tibgħat talba lis-servizz tal-konsumatur tagħna u aħna ninnotifikawkom malli nkunu nistgħu niksbuhom.
Ibgħat talba.
Ibgħat talba.
Ingredjent attiv:
ZANAMIVIR MICRONIZED
Disponibbli minn:
GLAXO SMITH KLINE (ISRAEL) LTD
Kodiċi ATC:
J05AH01
Għamla farmaċewtika:
POWDER FOR INHALATION
Kompożizzjoni:
ZANAMIVIR MICRONIZED 5 MG
Rotta amministrattiva:
INHALATION
Tip ta 'preskrizzjoni:
Required
Manifatturat minn:
GLAXO SMITH KLINE AUSTRALIA PTY LTD
Grupp terapewtiku:
ZANAMIVIR
Żona terapewtika:
ZANAMIVIR
Indikazzjonijiet terapewtiċi:
Zanamivir is indicated for the treatment of both uncomplicated acute illness due to influenza A and B virus in adults and adolescents (> or = 12 years) who have been symptomatic for no more than 48 hours and pediatric patients 7 years and older who have been symptomatic for no more than 36 hours.
Data ta 'l-awtorizzazzjoni:
2017-03-26
